Researchers at the University of Edinburgh are working on engineering bacteria to convert chemicals derived from waste plastic bottles into L-DOPA, a key drug used to treat Parkinson’s disease. The project, led by chemist Stephen Wallace, ran from July 1 to September 20, 2022, and represents a striking convergence of two fields that rarely overlap: plastic recycling and pharmaceutical manufacturing. If the approach scales, it could simultaneously address mounting plastic pollution and reduce the cost of producing a drug that millions of patients depend on daily.
From Plastic Waste to a Parkinson’s Drug
The core idea is deceptively simple. Polyethylene terephthalate, or PET, is one of the most common plastics on Earth, found in beverage bottles and food packaging worldwide. When PET is broken down, it yields two chemical building blocks: terephthalic acid and ethylene glycol. As described in a detailed review of PET structure, these monomers are linked through ester bonds that can be cleaved by enzymes or chemical catalysts, creating a stream of small molecules that microbes can metabolize.
The Wallace group at Edinburgh set out to show that engineered Escherichia coli bacteria could take ethylene glycol, one of those PET-derived monomers, and through a series of metabolic steps transform it into L-DOPA. In this vision, discarded plastic bottles are first depolymerized into their constituent monomers. Those monomers then become feedstock for a fermentation process, where E. coli strains outfitted with synthetic metabolic pathways convert them into L-DOPA that can be purified and formulated as a pharmaceutical ingredient.
The University of Edinburgh project record confirms the effort’s scope: titled “Microbial Synthesis of L-DOPA from waste PET,” it lists Wallace as principal investigator, with a start date of July 1, 2022, and an end date of September 20, 2022. The project status is listed as finished. No peer-reviewed paper detailing the full PET-to-L-DOPA conversion has been published yet based on available sources, but the underlying science draws on several well-established lines of research that Wallace’s lab and others have validated independently.
How Bacteria Rewire Plastic Chemistry
The biological pathway from PET to L-DOPA relies on a chain of conversions, each supported by published research. Ethylene glycol can enter E. coli metabolism and be routed into the shikimate pathway, the cell’s natural route for building aromatic compounds. Work in the journal Metabolic Engineering has shown that engineered E. coli can indeed funnel ethylene glycol toward aromatic products such as L-tyrosine, a direct precursor of L-DOPA.
Once L-tyrosine is available inside the cell, additional enzymes can convert it into L-DOPA. A published study (source) has described how genome engineering and pathway balancing can enable E. coli to overproduce L-DOPA from simple carbon sources, using enzymatic activities that add the necessary hydroxyl group. Complementary work in Microbial Cell Factories demonstrated that the BL21 (DE3) strain can synthesize L-DOPA de novo from glucose when supplied with an appropriate cascade of heterologous enzymes and cofactor-regeneration systems.
These studies establish that the biological machinery for making L-DOPA inside bacteria is real and reproducible. The innovation in Wallace’s project is to swap the traditional sugar feedstocks for PET-derived carbon. Instead of feeding E. coli expensive, food-grade glucose, the process would rely on ethylene glycol streams produced by enzymatic or chemical depolymerization of waste plastic. The same logic has already been applied to other aromatic products: for example, earlier work on microbial synthesis of catechol from renewable substrates showed that carefully engineered shikimate pathways can deliver high titers of aromatic chemicals, as reported in a biocatalysis study.
Wallace Lab’s Broader Plastic-to-Pharma Platform
The L-DOPA project does not exist in isolation. Wallace’s group has developed a broader platform for turning PET-derived chemicals into pharmaceuticals, with the most detailed published evidence coming from a related effort targeting paracetamol. A paper in Nature Chemistry describes how the team used a phosphate-catalyzed Lossen rearrangement inside living E. coli to convert a PET-derived intermediate into para-aminophenol, which can then be transformed into paracetamol in a one-pot, whole-cell process.
This work shows that PET can be more than a waste problem: it can be a carbon source for high-value drugs. The paracetamol study reports that terephthalic-acid-derived intermediates can be fed into carefully designed microbial pathways to yield pharmaceutical intermediates that can be converted into paracetamol in a one-pot, whole-cell process, on timescales reported by the authors and with yields described in the paper. In the L-DOPA project, the same design philosophy is applied to a different branch of metabolism, routing PET-derived carbon toward tyrosine and dopamine-related pathways rather than toward paracetamol precursors.
Taken together, the paracetamol and L-DOPA efforts suggest a modular “plastic-to-pharma” platform. In principle, once PET is broken into its monomers, different engineered strains could be deployed to manufacture a portfolio of drugs, each tuned to convert the same waste inputs into a distinct therapeutic molecule.
Why the PET-to-L-DOPA Link Matters
Most research and media attention on plastic-eating microbes has focused on environmental cleanup: breaking PET into harmless byproducts or recycling it back into new plastic. The field has advanced quickly. A recent review in environmental chemical engineering concluded that PET bio-recycling has evolved from simple degradation toward integrated strategies that combine efficient depolymerization, product recovery and lifecycle analysis.
Yet recycling PET back into PET often struggles to compete with cheap virgin plastic, limiting commercial uptake. Converting plastic waste into a high-value pharmaceutical ingredient like L-DOPA could change that calculus. L-DOPA is a relatively complex aromatic amino acid that commands a far higher price per kilogram than bulk plastics, and demand is expected to grow as populations age and Parkinson’s diagnoses increase. If engineered bacteria can make L-DOPA efficiently from PET-derived carbon, the economic incentive to collect and process waste bottles could become much stronger.
There are also potential supply-chain benefits. Today, most industrial L-DOPA production relies on petrochemical synthesis or fermentation processes that start from food-related sugars. A PET-based route could, in theory, decouple at least part of the supply from agricultural inputs and fossil feedstocks, diversifying production options. For regions grappling with both plastic pollution and constrained access to medicines, such a technology could be particularly attractive.
Scientific and Practical Hurdles Ahead
Despite the promise, significant challenges remain before PET-to-L-DOPA biomanufacturing can move from short exploratory projects to industrial reality. One hurdle is efficiency: each metabolic step from ethylene glycol to L-tyrosine and then to L-DOPA introduces potential losses, byproducts and toxicity issues. The published L-DOPA overproduction strains were optimized for sugar feedstocks, not for PET-derived monomers, so further engineering will be needed to achieve comparable yields and productivities with ethylene glycol inputs.
Another challenge is integration with PET depolymerization technologies. Current enzymatic and chemical methods for breaking down PET vary in cost, speed and compatibility with fermentation. Any viable process will need to match depolymerization rates with microbial uptake, while dealing with impurities, additives and dyes present in real-world plastic waste. Downstream, efficient separation of L-DOPA from fermentation broth and residual contaminants will be essential to meet stringent pharmaceutical quality standards.
Finally, regulatory and economic questions loom large. Using waste-derived feedstocks for drug manufacturing raises questions about traceability and quality control, even if purification steps remove impurities. Regulators will likely require extensive validation to ensure that L-DOPA made from PET is chemically identical and equally safe compared with existing products. On the economic side, the cost of depolymerizing, fermenting and purifying must be competitive with entrenched production routes, which benefit from decades of optimization.
A Glimpse of a Circular Pharmaceutical Future
Even with these caveats, the Edinburgh team’s work offers a compelling glimpse of how synthetic biology and green chemistry might reshape both waste management and drug manufacturing. By demonstrating that the same waste plastic that clogs rivers and landfills can, in principle, be transformed into frontline medicines, the project challenges assumptions about what counts as a valuable resource.
For now, the PET-to-L-DOPA route remains at an early stage, supported by a short, focused project rather than a full industrial pipeline. But the scientific building blocks are in place: microbes that digest PET monomers, strains that overproduce L-DOPA, and proof-of-concept platforms that turn plastic-derived intermediates into drugs like paracetamol. If future work can knit these elements into robust, scalable processes, plastic bottles might one day serve not just as containers for beverages, but as the starting point for life-changing therapies.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
